MAXCYTE INC (MXCT) Fundamental Analysis & Valuation

NASDAQ:MXCT • US57777K1060

Current stock price

0.71 USD
0 (-0.57%)
At close:
0.7047 USD
-0.01 (-0.75%)
After Hours:

This MXCT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. MXCT Profitability Analysis

1.1 Basic Checks

  • MXCT had negative earnings in the past year.
  • In the past year MXCT has reported a negative cash flow from operations.
  • MXCT had negative earnings in each of the past 5 years.
  • MXCT had a negative operating cash flow in each of the past 5 years.
MXCT Yearly Net Income VS EBIT VS OCF VS FCFMXCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M -50M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -22.04%, MXCT is doing worse than 68.42% of the companies in the same industry.
  • MXCT has a Return On Equity of -26.02%. This is comparable to the rest of the industry: MXCT outperforms 43.86% of its industry peers.
Industry RankSector Rank
ROA -22.04%
ROE -26.02%
ROIC N/A
ROA(3y)-17.77%
ROA(5y)-13.65%
ROE(3y)-20.75%
ROE(5y)-15.76%
ROIC(3y)N/A
ROIC(5y)N/A
MXCT Yearly ROA, ROE, ROICMXCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80

1.3 Margins

  • MXCT's Gross Margin of 81.16% is amongst the best of the industry. MXCT outperforms 96.49% of its industry peers.
  • In the last couple of years the Gross Margin of MXCT has declined.
  • The Profit Margin and Operating Margin are not available for MXCT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 81.16%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.84%
GM growth 5Y-1.92%
MXCT Yearly Profit, Operating, Gross MarginsMXCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. MXCT Health Analysis

2.1 Basic Checks

  • MXCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, MXCT has more shares outstanding
  • Compared to 5 years ago, MXCT has more shares outstanding
  • There is no outstanding debt for MXCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MXCT Yearly Shares OutstandingMXCT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
MXCT Yearly Total Debt VS Total AssetsMXCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • Based on the Altman-Z score of -0.28, we must say that MXCT is in the distress zone and has some risk of bankruptcy.
  • MXCT has a worse Altman-Z score (-0.28) than 73.68% of its industry peers.
  • There is no outstanding debt for MXCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.28
ROIC/WACCN/A
WACC10.95%
MXCT Yearly LT Debt VS Equity VS FCFMXCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M 200M 250M

2.3 Liquidity

  • A Current Ratio of 8.30 indicates that MXCT has no problem at all paying its short term obligations.
  • MXCT has a better Current ratio (8.30) than 92.98% of its industry peers.
  • MXCT has a Quick Ratio of 7.77. This indicates that MXCT is financially healthy and has no problem in meeting its short term obligations.
  • MXCT has a Quick ratio of 7.77. This is amongst the best in the industry. MXCT outperforms 94.74% of its industry peers.
Industry RankSector Rank
Current Ratio 8.3
Quick Ratio 7.77
MXCT Yearly Current Assets VS Current LiabilitesMXCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. MXCT Growth Analysis

3.1 Past

  • MXCT shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.13%.
  • The Revenue for MXCT has decreased by -14.50% in the past year. This is quite bad
  • The Revenue has been growing slightly by 4.76% on average over the past years.
EPS 1Y (TTM)5.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
Revenue 1Y (TTM)-14.5%
Revenue growth 3Y-9.3%
Revenue growth 5Y4.76%
Sales Q2Q%-16.02%

3.2 Future

  • The Earnings Per Share is expected to grow by 14.87% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 32.62% on average over the next years. This is a very strong growth
EPS Next Y25.21%
EPS Next 2Y17.84%
EPS Next 3Y13.15%
EPS Next 5Y14.87%
Revenue Next Year-8.93%
Revenue Next 2Y4.05%
Revenue Next 3Y17.26%
Revenue Next 5Y32.62%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MXCT Yearly Revenue VS EstimatesMXCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
MXCT Yearly EPS VS EstimatesMXCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

0

4. MXCT Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MXCT. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MXCT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MXCT Price Earnings VS Forward Price EarningsMXCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MXCT Per share dataMXCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as MXCT's earnings are expected to grow with 13.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.84%
EPS Next 3Y13.15%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MXCT Dividend Analysis

5.1 Amount

  • MXCT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MXCT Fundamentals: All Metrics, Ratios and Statistics

MAXCYTE INC

NASDAQ:MXCT (4/7/2026, 4:04:23 PM)

After market: 0.7047 -0.01 (-0.75%)

0.71

0 (-0.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)03-24
Earnings (Next)05-04
Inst Owners71.23%
Inst Owner Change0.43%
Ins Owners1.32%
Ins Owner Change2.24%
Market Cap75.74M
Revenue(TTM)33.03M
Net Income(TTM)-44.63M
Analysts83.08
Price Target4.9 (590.14%)
Short Float %5.5%
Short Ratio4.45
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.13%
Min EPS beat(2)19.79%
Max EPS beat(2)26.47%
EPS beat(4)3
Avg EPS beat(4)9.76%
Min EPS beat(4)-13.86%
Max EPS beat(4)26.47%
EPS beat(8)7
Avg EPS beat(8)16.71%
EPS beat(12)9
Avg EPS beat(12)13.46%
EPS beat(16)13
Avg EPS beat(16)16.7%
Revenue beat(2)0
Avg Revenue beat(2)-21.96%
Min Revenue beat(2)-23.91%
Max Revenue beat(2)-20.01%
Revenue beat(4)1
Avg Revenue beat(4)-12.78%
Min Revenue beat(4)-23.91%
Max Revenue beat(4)5.28%
Revenue beat(8)5
Avg Revenue beat(8)5.38%
Revenue beat(12)7
Avg Revenue beat(12)2.5%
Revenue beat(16)10
Avg Revenue beat(16)3.81%
PT rev (1m)-14.88%
PT rev (3m)-24.3%
EPS NQ rev (1m)-28%
EPS NQ rev (3m)-25%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.73%
Revenue NQ rev (1m)-17.36%
Revenue NQ rev (3m)-17.39%
Revenue NY rev (1m)-16.93%
Revenue NY rev (3m)-18.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.29
P/FCF N/A
P/OCF N/A
P/B 0.44
P/tB 0.44
EV/EBITDA N/A
EPS(TTM)-0.37
EYN/A
EPS(NY)-0.28
Fwd EYN/A
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.32
OCFYN/A
SpS0.31
BVpS1.61
TBVpS1.6
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -22.04%
ROE -26.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 81.16%
FCFM N/A
ROA(3y)-17.77%
ROA(5y)-13.65%
ROE(3y)-20.75%
ROE(5y)-15.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.84%
GM growth 5Y-1.92%
F-Score3
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.74%
Cap/Sales 5.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.3
Quick Ratio 7.77
Altman-Z -0.28
F-Score3
WACC10.95%
ROIC/WACCN/A
Cap/Depr(3y)55.9%
Cap/Depr(5y)224.37%
Cap/Sales(3y)6.2%
Cap/Sales(5y)14.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
EPS Next Y25.21%
EPS Next 2Y17.84%
EPS Next 3Y13.15%
EPS Next 5Y14.87%
Revenue 1Y (TTM)-14.5%
Revenue growth 3Y-9.3%
Revenue growth 5Y4.76%
Sales Q2Q%-16.02%
Revenue Next Year-8.93%
Revenue Next 2Y4.05%
Revenue Next 3Y17.26%
Revenue Next 5Y32.62%
EBIT growth 1Y13.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year45.13%
EBIT Next 3Y15.78%
EBIT Next 5Y15.97%
FCF growth 1Y-23.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.63%
OCF growth 3YN/A
OCF growth 5YN/A

MAXCYTE INC / MXCT Fundamental Analysis FAQ

What is the fundamental rating for MXCT stock?

ChartMill assigns a fundamental rating of 3 / 10 to MXCT.


Can you provide the valuation status for MAXCYTE INC?

ChartMill assigns a valuation rating of 0 / 10 to MAXCYTE INC (MXCT). This can be considered as Overvalued.


Can you provide the profitability details for MAXCYTE INC?

MAXCYTE INC (MXCT) has a profitability rating of 1 / 10.


What is the financial health of MAXCYTE INC (MXCT) stock?

The financial health rating of MAXCYTE INC (MXCT) is 7 / 10.